

REMARKS

Claims 12-24 are now pending, with Claim 12 being the sole independent claim.

Claims 1-11 have been canceled without prejudice to or disclaimer of the subject matter recited therein.

Claims 12-24 have been added. Support for these added claims can be found at least in the claims as originally filed and throughout the specification. Thus, no new matter has been added.

RESPONSE TO RESTRICTION REQUIREMENT

Applicants hereby elect, without traverse, the subject matter of Invention I, Claims 1-5, 10 and 11, drawn to a polynucleotide. This election is made subject to Applicants' right to pursue the non-elected subject matter in a divisional application or applications pursuant to 35 U.S.C. §121.

Applicants further elect, without traverse, the subject matter of Group I, drawn to SEQ ID NO:17 or SEQ ID NO:18. SEQ ID NO:18 is an amino acid sequence encoded by nucleotides 2-2044 of SEQ ID NO:17. Applicants note that there is an ATG codon at position 71-73 and the termination codon is at position 2042-2044 (TGA). The start methionine in SEQ ID NO:18 can be found at position 35.

Applicants respectfully submit that now pending Claims 12-24 are directed to the subject matter of Invention I and Group I.

Please charge any fees or credit any overpayment of fees which are required in connection with the filing of this Preliminary Amendment and Response to Restriction Requirement to Deposit Account No. 04-1928 (E. I. du Pont de Nemours and Company).

Allowance of the above-referenced application is respectfully requested in view of the foregoing.

Respectfully submitted,

Dawn S. Clark

DAWN S. CLARK
AGENT FOR APPLICANTS
REGISTRATION NO. 42,420
TELEPHONE: 302-695-1080
FACSIMILE: 302-695-3125

Dated: August 8, 2005